methane has been researched along with Inflammatory Bowel Diseases in 12 studies
Methane: The simplest saturated hydrocarbon. It is a colorless, flammable gas, slightly soluble in water. It is one of the chief constituents of natural gas and is formed in the decomposition of organic matter. (Grant & Hackh's Chemical Dictionary, 5th ed)
methane : A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC).
Inflammatory Bowel Diseases: Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lactose intolerance is the most prevalent intestinal malabsorption disorder." | 8.91 | [Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015) |
| "Lactose intolerance is the most prevalent intestinal malabsorption disorder." | 4.91 | [Lactose intolerance: past and present. Part 1]. ( Buzás, GM, 2015) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| " Since there are two gases (hydrogen and methane) measured on lactulose breath testing, we evaluated whether the different gas patterns on lactulose breath testing coincide with diarrhea and constipation symptoms in IBS and IBD." | 3.72 | Methane production during lactulose breath test is associated with gastrointestinal disease presentation. ( Chow, EJ; Hasan, A; Kong, Y; Mayer, AG; Park, S; Pimentel, M, 2003) |
| "Hydrogen sulphide is a by-product of H(2) metabolism by SRB, which are ubiquitous in the colonic mucosa." | 2.48 | Contributions of the microbial hydrogen economy to colonic homeostasis. ( Benefiel, AC; Carbonero, F; Gaskins, HR, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, N | 1 |
| Wang, Z | 1 |
| Wang, C | 1 |
| Zhang, J | 1 |
| Liu, C | 1 |
| Ding, XW | 1 |
| Liu, YX | 1 |
| Fang, XC | 1 |
| Liu, K | 1 |
| Wei, YY | 1 |
| Shan, MH | 1 |
| Ross, EM | 1 |
| Moate, PJ | 1 |
| Marett, LC | 1 |
| Cocks, BG | 1 |
| Hayes, BJ | 1 |
| Lee, JM | 1 |
| Lee, KM | 1 |
| Chung, YY | 1 |
| Lee, YW | 1 |
| Kim, DB | 1 |
| Sung, HJ | 1 |
| Chung, WC | 1 |
| Paik, CN | 1 |
| Buzás, GM | 1 |
| Eadala, P | 1 |
| Matthews, SB | 1 |
| Waud, JP | 1 |
| Green, JT | 1 |
| Campbell, AK | 1 |
| Nakamura, N | 1 |
| Lin, HC | 1 |
| McSweeney, CS | 1 |
| Mackie, RI | 1 |
| Gaskins, HR | 2 |
| Carbonero, F | 1 |
| Benefiel, AC | 1 |
| Pimentel, M | 1 |
| Mayer, AG | 1 |
| Park, S | 1 |
| Chow, EJ | 1 |
| Hasan, A | 1 |
| Kong, Y | 1 |
| Yue, NN | 1 |
| Xu, HM | 1 |
| Xu, J | 1 |
| Zhu, MZ | 1 |
| Zhang, Y | 1 |
| Tian, CM | 1 |
| Nie, YQ | 1 |
| Yao, J | 1 |
| Liang, YJ | 1 |
| Li, DF | 1 |
| Wang, LS | 1 |
| Wang, Q | 1 |
| Subramanian, P | 1 |
| Schechter, A | 1 |
| Teblum, E | 1 |
| Yemini, R | 1 |
| Nessim, GD | 1 |
| Vasilescu, A | 1 |
| Li, M | 1 |
| Boukherroub, R | 1 |
| Szunerits, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of the Efficacy and Safety of Single, Daily Oral Doses of SYN-010 Compared to Placebo in Adult Patients With Irritable Bowel Syndrome With Constipation (EASE-DO)[NCT03763175] | Phase 2 | 59 participants (Actual) | Interventional | 2018-12-24 | Terminated (stopped due to Interim Futility Analysis) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing single-point breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing course of SYN-010
| Intervention | particles per million (Mean) |
|---|---|
| SYN-010 21 mg | -22.623 |
| SYN-010 42 mg | -4.785 |
| Placebo | -10.081 |
Subjects will record their daily bowel movements throughout the duration of the study. Change in weekly average number of CSBMs will be evaluated by comparing reported values pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Weekly average CSBMs (Least Squares Mean) |
|---|---|
| SYN-010 21 mg | 1.53 |
| SYN-010 42 mg | 0.32 |
| Placebo | 0.51 |
Change in exhaled methane level as a potential predictor of constipation improvement will be evaluated by comparing lactulose breath tests pre- and post-treatment. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | particles per million * min (Mean) |
|---|---|
| SYN-010 21 mg | -18.678 |
| SYN-010 42 mg | -20.137 |
| Placebo | -39.199 |
An overall abdominal pain intensity responder is defined as a patient with a weekly abdominal pain intensity response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response abdominal pain intensity response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 4 |
| Placebo | 7 |
An overall bloating responder is defined as a patient with a weekly bloating response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly bloating response is defined as a weekly average bloating score of at least 30% improvement compared to baseline, with stool frequency unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 3 |
| SYN-010 42 mg | 3 |
| Placebo | 1 |
An overall 12-week responder is defined as a patient with a weekly response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly response is defined as a decrease in the patient's weekly average score for worst abdominal pain in the past 24 hours of at least 30% compared to baseline and a stool frequency increase of 1 or more CSBMs per week compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
An overall stool frequency responder is defined as a patient with a weekly stool frequency response in at least 50% of the weeks of treatment (6 of 12 weeks). A weekly stool frequency response is defined as a stool frequency increase of 1 or more CSBMs per week compared with baseline, with abdominal pain unchanged or improved compared with baseline. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 4 |
| SYN-010 42 mg | 6 |
| Placebo | 9 |
Subjects will record their use of rescue medication throughout the study period. Proportion of patients using rescue medication after completing the 12-week course of treatment will be compared to those reporting usage at baseline screening period. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 9 |
| SYN-010 42 mg | 11 |
| Placebo | 8 |
Outcome will be assessed by evaluating proportion of patients reporting adequate relief pre- and post-treatment on validated questionnaire. (NCT03763175)
Timeframe: After completing 12-week course of SYN-010
| Intervention | Participants (Count of Participants) |
|---|---|
| SYN-010 21 mg | 1 |
| SYN-010 42 mg | 2 |
| Placebo | 6 |
5 reviews available for methane and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
[Lactose intolerance: past and present. Part 1].
Topics: Animals; Biopsy; Breath Tests; Celiac Disease; Europe; Genetic Testing; Global Health; History, 17th | 2015 |
Mechanisms of microbial hydrogen disposal in the human colon and implications for health and disease.
Topics: Acetic Acid; Colon; Colorectal Neoplasms; Humans; Hydrogen; Inflammatory Bowel Diseases; Methane; Me | 2010 |
Contributions of the microbial hydrogen economy to colonic homeostasis.
Topics: Bacteria; Carbon Dioxide; Colon; Colonic Diseases; Colorectal Neoplasms; Homeostasis; Humans; Hydrog | 2012 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Application of Nanoparticles in the Diagnosis of Gastrointestinal Diseases: A Complete Future Perspective.
Topics: Gastrointestinal Diseases; Gastrointestinal Neoplasms; Humans; Inflammatory Bowel Diseases; Nanopart | 2023 |
1 trial available for methane and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
7 other studies available for methane and Inflammatory Bowel Diseases
| Article | Year |
|---|---|
Methane Alleviates Inflammation and Apoptosis of Dextran Sulfate Sodium-Induced Inflammatory Bowel Diseases by Inhibiting Toll-Like Receptor 4 (TLR4)/Myeloid Differentiation Factor 88 (MyD88)/Nuclear Translocation of Nuclear Factor-κB (NF-κB) and Endoplas
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Dextran Sulfate; Disease Models, Animal; Endoplasmic R | 2020 |
The relationship between small intestinal bacterial overgrowth and irritable bowel syndrome.
Topics: Adult; Aged; Breath Tests; Female; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Hydrog | 2017 |
Metagenomic predictions: from microbiome to complex health and environmental phenotypes in humans and cattle.
Topics: Animals; Cattle; Environment; Health; Humans; Inflammatory Bowel Diseases; Metagenomics; Methane; Mi | 2013 |
Clinical significance of the glucose breath test in patients with inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Breath Tests; Feces; Female; Glucose; Humans; Hydrogen; | 2015 |
Association of lactose sensitivity with inflammatory bowel disease--demonstrated by analysis of genetic polymorphism, breath gases and symptoms.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Breath Tests; Chi-Square Distribution; Female; | 2011 |
Methane production during lactulose breath test is associated with gastrointestinal disease presentation.
Topics: Breath Tests; Colitis, Ulcerative; Constipation; Crohn Disease; Databases, Factual; Gastrointestinal | 2003 |
Vertically Aligned Nitrogen-Doped Carbon Nanotube Carpet Electrodes: Highly Sensitive Interfaces for the Analysis of Serum from Patients with Inflammatory Bowel Disease.
Topics: Electrochemistry; Electrodes; Humans; Inflammatory Bowel Diseases; Muramidase; Nanotubes, Carbon; Ni | 2016 |